Allied-Bristol Life Sciences, LLC, a biopharmaceutical enterprise
jointly owned between Allied Minds ALM and Bristol-Myers Squibb
Company BMY, announced that it has entered into a worldwide
licensing agreement with Yale University for a proprietary platform
technology and associated lead molecules that will be further developed
to treat diseases such as prostate cancer, a leading cause of
cancer-related deaths among American men.
Developed by Professor David A. Spiegel, Ph.D., M.D. and his team at
Yale University, the proprietary synthetic molecules, known as Antibody
Recruiting Molecules (ARMs), work by harnessing the power of the body's
own immune system to treat cancer. The ARMs do this by recruiting
antibodies already present in the bloodstream and then leading
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in